Search Patents
-
Patent number: 8835107Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.Type: GrantFiled: July 26, 2010Date of Patent: September 16, 2014Assignee: Amsterdam Institute of Viral Genomics B.V.Inventor: Cornelia Maria Van Der Hoek
-
Patent number: 7527926Abstract: This invention provides oligonucleotides, reagents and amplification methods for detecting the severe acute respiratory syndrome coronavirus (SARS CoV). This invention also provides related compositions, kits, systems, and computers.Type: GrantFiled: April 21, 2004Date of Patent: May 5, 2009Assignee: Genome Institute of SingaporeInventors: Ee Chee Ren, Martin L. Hibberd, Lisa Fong Poh Ng
-
Patent number: 8106172Abstract: The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with a novel human coronavirus causing Severe Acute Respiratory Syndrome (SARS). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of SARS nucleic acid. The oligonucleotide sequences provided with the present invention are located in the replicase gene, the nucleocapsid gene and the 3? end non-coding region of the SARS Coronavirus genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of SARS Coronavirus can be obtained. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.Type: GrantFiled: March 8, 2004Date of Patent: January 31, 2012Assignee: Biomerieux, B.V.Inventors: Peter T. G. Sillekens, Marlieke Overdijk, Saskia van de Laar
-
Patent number: 7582740Abstract: The present invention provides a synthetic nucleic acid sequence comprising 10-30 nucleotides of the N gene region and/or the 3? non-coding region of the SARS-associated coronavirus genome, and a synthetic nucleic acid sequence comprising 10-30 nucleotides of a nucleic acid sequence that is complementary to at least one of those regions. Also provided are compositions comprising the sequences, and uses of the sequences in diagnostic kits. The present invention further provides a primer set for determining the presence or absence of SARS-associated coronavirus in a biological sample, wherein the primer set comprises at least one of the synthetic nucleic acid sequences. Also provided are a composition comprising the primer set, and use of the primer set in a diagnostic kit. Finally, the present invention provides kits and methods for determining the presence or absence of SARS-associated coronavirus in a biological sample.Type: GrantFiled: January 23, 2004Date of Patent: September 1, 2009Assignee: The Trustees of Columbia University In the City of New YorkInventors: Thomas Briese, W. Ian Lipkin, Gustavo Palacios, Omar Jabado
-
Patent number: 6867021Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.Type: GrantFiled: February 20, 2001Date of Patent: March 15, 2005Assignee: Board of Trustees of Michigan State UniversityInventors: Roger K. Maes, Annabel G. Wise
-
Publication number: 20110065089Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: ApplicationFiled: April 6, 2010Publication date: March 17, 2011Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Patent number: 7736850Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: GrantFiled: December 2, 2004Date of Patent: June 15, 2010Assignees: Institute Pasteur, Centre National de la Recherche Scientifique, Universite Paris 7Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Patent number: 7776521Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.Type: GrantFiled: May 14, 2007Date of Patent: August 17, 2010Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Paul A. Rota, Larry J. Anderson, William J. Bellini, Michael D. Bowen, Cara Carthel Burns, Raymond Campagnoli, Qi Chen, James A. Comer, Byron T. Cook, Shannon L. Emery, Dean D. Erdman, Cynthia S. Goldsmith, Jeanette Guarner, Charles D. Humphrey, Joseph P. Icenogle, Thomas G. Ksiazek, Richard F. Meyer, Stephan S. Monroe, William Allan Nix, M. Steven Oberste, Christopher D. Paddock, Teresa C. T. Peret, Pierre E. Rollin, Mark A. Pallansch, Anthony Sanchez, Wun-Ju Shieh, Suxiang Tong, Sherif R. Zaki
-
Publication number: 20080194422Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.Type: ApplicationFiled: April 21, 2008Publication date: August 14, 2008Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Hee-kyun LIM, Sang-hyo KIM, Jung-joo HWANG, Young-sun LEE, Young-a KIM
-
Patent number: 7375210Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.Type: GrantFiled: November 24, 2004Date of Patent: May 20, 2008Assignee: Samsung Electronics Co., Ltd.Inventors: Hee-kyun Lim, Sang-hyo Kim, Jung-joo Hwang, Young-sun Lee, Young-a Kim
-
Publication number: 20090258340Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.Type: ApplicationFiled: February 3, 2009Publication date: October 15, 2009Applicant: Becton, Dickinson and CompanyInventors: Jianrong Lou, James A. Price, JR., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin Hellyer
-
Publication number: 20100136513Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the nucleocapsid gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARSCoV infection.Type: ApplicationFiled: September 13, 2004Publication date: June 3, 2010Inventors: Jianrong Lou, James A. Price, JR., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin J. Hellyer
-
Patent number: 7723041Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.Type: GrantFiled: February 3, 2009Date of Patent: May 25, 2010Assignee: Becton, Dickinson and CompanyInventors: Jianrong Lou, James A. Price, Jr., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin Hellyer
-
Patent number: 7521185Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.Type: GrantFiled: September 13, 2004Date of Patent: April 21, 2009Assignee: Becton, Dickinson and CompanyInventors: Jianrong Lou, James A. Price, Jr., Daretta A. Yursis, David M. Wolfe, Lisa M. Keller, Tobin J. Hellyer
-
Patent number: 7129223Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.Type: GrantFiled: May 19, 2004Date of Patent: October 31, 2006Assignee: The University of HongKongInventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
-
Patent number: 7547512Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.Type: GrantFiled: March 24, 2004Date of Patent: June 16, 2009Assignee: The University of Hong KongInventors: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung